News Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
16.16 ^USD	-5.28%		-15.83%	-40.26%

Apr. 15	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
Apr. 03	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	BU
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	CI
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study	Mar. 25	AQ
Blood test shows 83% accuracy for detecting colorectal cancer in trial	Mar. 13	AQ
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine	Mar. 13	BU
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer	Mar. 13	CI
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	BU
Guardant Health, Inc. - New Survey, Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	Mar. 04	AQ
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	Mar. 01	BU
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM	Feb. 29
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	Feb. 26	MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating	Feb. 23	MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating	Feb. 23	MT
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises	Feb. 23	MT
Guardant Health: Q4 Earnings Snapshot	Feb. 22	AQ
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $155.1M, vs. Street Est of $150.8M	Feb. 22	MT
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook	Feb. 22	BU
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024	Feb. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Guardant Health, Inc.

Equities

GH

US40131M1099

Summary

Filters